Immuneering has appointed Grant C. Bogle to its board, adding a new director as of Nov. 9, 2026. The appointment is a governance change; the announcement does not describe any accompanying shift in the company’s strategy or management.
- Bogle will serve as a Class III director.
- He will receive compensation under Immuneering’s standard arrangements for directors who are not company employees.
- He has not been assigned to a board committee.
- Immuneering said there was no arrangement or understanding behind his appointment. Bogle also signed the company’s standard indemnification agreement for directors and officers.
The disclosed change is limited to adding Bogle to the board; no committee responsibilities were announced.